I spoke with an FDA representative this morning. There are models we can follow for this type of approval and others that are still in development. Overall though, it will take input from the patient community and input from researchers and physicians. In regards to clinical trials: a secondary endpoint will be taken under consideration which then, if met, can drive accelerated approval. The good news is that we are not at a standstill.
THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER